1.上海中医药大学附属龙华医院心病科(上海 200032)
张一凡,女,博士研究生,主要从事中西医结合防治动脉粥样硬化研究工作
刘萍,主任医师,博士研究生导师; E-mail:liuping0207@126.com
扫 描 看 全 文
张一凡,刘萍,王怡茹等.冠心康对动脉粥样硬化LDLR-/-小鼠肝组织MAPKs/NF⁃κB信号通路相关蛋白表达的影响[J].上海中医药杂志,2022,56(04):79-85.
ZHANG Yifan,LIU Ping,WANG Yiru,et al.Effect of Guanxinkang on expression of proteins related to MAPKs/NF⁃κB signal pathway in liver tissue of LDLR-/-mice with atherosclerosis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(04):79-85.
张一凡,刘萍,王怡茹等.冠心康对动脉粥样硬化LDLR-/-小鼠肝组织MAPKs/NF⁃κB信号通路相关蛋白表达的影响[J].上海中医药杂志,2022,56(04):79-85. DOI: 10.16305/j.1007-1334.2022.2102026.
ZHANG Yifan,LIU Ping,WANG Yiru,et al.Effect of Guanxinkang on expression of proteins related to MAPKs/NF⁃κB signal pathway in liver tissue of LDLR-/-mice with atherosclerosis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(04):79-85. DOI: 10.16305/j.1007-1334.2022.2102026.
目的,2,观察冠心康对LDLR,-/-,小鼠肝组织MAPKs/NF-κB信号通路相关蛋白表达的影响。,方法,2,将24只雄性LDLR,-/-,小鼠随机分为模型组,冠心康低、中、高剂量组,以C57BL/6J小鼠为对照组。除对照组外,每组给予高脂饲料喂养12周。对照组、模型组每日给予200 μL 0.9%NaCl溶液灌胃,冠心康低、中、高剂量组分别每日给予7.24 g/kg、14.48 g/kg、28.96 g/kg的中药煎剂200 μL灌胃,共12周。采用生化检测方法检测小鼠血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆固醇(TC)、三酰甘油(TG)水平;油红O染色法观察小鼠斑块面积;HE染色法观察小鼠肝组织结构;Western blot测定细胞外调节蛋白激酶(Erk1/2),分子量为38 kDa的促分裂素愿活化蛋白激酶(P38),c-Jun氨基末端激酶(JNK),核因子κB抑制蛋白(IκB),核因子κB蛋白表达(NF-κB);RT-PCR、ELISA法检测白介素-1β(IL-1β)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α) mRNA及含量;免疫荧光法观察TNF-α表达。,结果,2,与模型组比较,冠心康各剂量组小鼠血清TC、TG、ALT、AST水平降低(,P,<,0.05),主动脉斑块面积减少,肝组织病理变化改善,肝组织Erk1/2,P38,JNK,IκB,NF-κB水平降低(,P,<,0.05),肝组织,IL,-,1β,、,IL,-,6,、,TNF,-,α, mRNA表达下调(,P,<,0.05),血清IL-1β、IL-6、TNF-α含量减少(,P,<,0.05),肝组织TNF-α表达减少(,P,<,0.05)。,结论,2,冠心康可通过抑制MAPKs/NF-κB信号通路,减轻LDLR,-/-,小鼠肝脏炎症,进而改善动脉粥样硬化。
Objective,2,To observe the effect of Guanxinkang (GXK) on the expression of proteins related to MAPKs/NF-κB signal pathway in the liver tissue of LDLR,-/-, mice.,Methods,2,Twenty-four male LDLR,-/-, mice were randomly divided into model group, GXK low, medium and high dose groups, and C57BL/6J mice were used as the control group. Except for the control group, each group was given high-fat feed for 12 weeks. The control group and the model group were given 200 μL of 0.9% NaCl solution daily. The GXK low, medium and high dose groups were given 7.24 g/kg, 14.48 g/kg, 28.96 g/kg of Chinese medicine decoction, 200 μL daily for 12 weeks. The serum levels of TC, TG, ALT and AST were detected by biochemical assay; the plaque area was observed by oil red O staining; the liver tissue structure was observed by hematoxylin-eosin (HE) staining; the expressions of Erk1/2, P38, JNK, IκB, NF-κB proteins were determined by Western blot; the mRNA and contents of IL-1, IL-6 and TNF-α were detected by RT-PCR and ELISA respectively; and the expression of TNF-α was observed by immunofluorescence.,Results,2,Compared with the model group, the levels of serum TC, TG, ALT and AST were decreased in each dose group of GXK (,P,<,0.05); the area of aortic plaques was reduced and pathological changes in the liver tissue were improved. And the phosphorylation level of Erk1/2, P38, JNK, IκB, and NF-κB protein in liver tissue was decreased in GXK groups (,P,<,0.05). The expressions of IL-1β, IL-6, TNF-α mRNA in the liver tissue were down-regulated in GXK groups (,P,<,0.05). The contents of IL-1β, IL-6 and TNF-α in serum were decreased (,P,<,0.05) and the expression of TNF- α in liver tissue was reduced.,Conclusion,2,GXK can reduce liver inflammation and improve atherosclerosis in LDLR,-/-, mice by inhibiting MAPKs/ NF-κB signal pathway.
冠心康动脉粥样硬化MAPKs/NF-kB信号通路炎症模型小鼠中药研究
GuanxinkangatherosclerosisMAPKs/NF-κB signal pathwayinflammationmodel miceChinese herbal medicine research
VIRANI S S, ALONSO A, BENJAMIN E J, et al. Heart disease and stroke statistics-2020 update: a report from the american heart association[J]. Circulation, 2020, 141(9): 139-596.
ANDERSSON C, VASAN R S. Epidemiology of cardiovascular disease in young individuals[J]. Nat Rev Cardiol, 2018, 15(4): 230-240.
CONTE S M, VALE P R. Peripheral arterial disease[J]. Heart Lung Circ, 2018, 27(4): 427-432.
CHRISTODOULIDIS G, VITTORIO T J, FUDIM M, et al. Inflammation in coronary artery disease[J]. Cardiol Rev, 2014, 22(6): 279-288.
李文毅,周春阳. 高脂血症与动脉粥样硬化和脂代谢研究进展[J]. 中国药理学与毒理学杂志,2019,33(10):811.
ROBINSON M W, HARMON C, O'FARRELLY C. Liver immunology and its role in inflammation and homeostasis[J]. Cell Mol Immunol, 2016, 13(3): 267-276.
ALVES-BEZERRA M, COHEN D E. Triglyceride metabolism in the liver[J]. Compr Physiol, 2017, 8(1): 1-8.
庄欣,张蕴慧. 从肝论治心血管疾病举隅[J]. 中华中医药杂志,2005, 20(1): 50-51.
张守刚,刘小雨,孙鑫. 心病从肝论治思维探析[J]. 上海中医药杂志,2011, 45(6): 28-30.
LEE Y T, LIN H Y, CHAN Y W, et al. Mouse models of atherosclerosis: a historical perspective and recent advances[J]. Lipids Health Dis, 2017, 16(1): 12-18.
BRUNT E M, KLEINER D E, WILSON L A, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings[J]. Hepatology, 2011, 53(3): 810-820.
SCHAFTENAAR F, FRODERMANN V, KUIPER J, et al. Atherosclerosis: the interplay between lipids and immune cells[J]. Curr Opin Lipidol, 2016, 27(3): 209-215.
JONES J G. Hepatic glucose and lipid metabolism[J]. Diabetologia, 2016, 59(6): 1098-1103.
DUNN W, XU R, WINGARD D L, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study[J]. Am J Gastroenterol, 2008, 103(9): 2263-2271.
LONARDO A, LOMBARDINI S, SCAGLIONI F, et al. Fatty liver, carotid disease and gallstones: a study of age-related associations[J]. World J Gastroenterol, 2006, 12(36): 5826-5833.
毛美娇,胡俊萍,王从,等. 冠心康对ApoE-/-动脉粥样硬化小鼠PPARγ-LXRα-ABCA1信号通路的影响[J]. 中西医结合学报,2012, 10(7): 814-820.
ABDALLAH L R, DE MATOS R C, YPDM E S, et al. Non-alcoholic fatty liver disease and its links with inflammation and atherosclerosis[J]. Curr Atheroscler Rep, 2020, 22(1): 7.
KLEEMANN R, VERSCHUREN L, VAN ERK M J, et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis[J]. Genome Biology, 2007, 8(9): R200.
TARGHER G, DAY C P, BONORA E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363(14): 1341-1350.
YUN K E, SHIN C Y, YOON Y S, et al. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans[J]. Atherosclerosis, 2009, 205(2): 533-537.
REUSTLE A, TORZEWSKI M. Role of p38 MAPK in atherosclerosis and aortic valve sclerosis[J]. Int J Mol Sci, 2018, 19(12): 3761.
GUO Y J, PAN W W, LIU S B, et al. ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020, 19(3): 1997-2007.
ZHAO M, LIU Y, WANG X, et al. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL[J]. APMIS, 2010, 110(6):458-468.
YEUNG Y T, AZIZ F, GUERRERO-CASTILLA A, et al. Signaling pathways in inflammation and anti-inflammatory therapies[J]. Curr Pharm Des, 2018, 24(14): 1449-1484.
AN Z, LI J, YU J, et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages[J]. Cell cycle, 2019, 18(21): 2928-2938.
JIANG L, QIAO Y, WANG Z, et al. Inhibition of microRNA-103 attenuates inflammation and endoplasmic reticulum stress in atherosclerosis through disrupting the PTEN-mediated MAPK signaling[J]. J Cell Physiol, 2020, 235(1): 380-393.
WU Y, WANG F, FAN L, et al. Baicalin alleviates atherosclerosis by relieving oxidative stress and inflammatory responses via inactivating the NF-κB and p38 MAPK signaling pathways[J]. Biomed Pharmacother, 2018, 97(1): 1673-1679.
0
浏览量
451
下载量
0
CSCD
2
CNKI被引量
关联资源
相关文章
相关作者
相关机构